Reaktionsgleichung
C(OC(=O)[NH:7][C:8]([C:10]1[S:11][C:12]([S:36][CH3:37])=[C:13]([S:15]([C:18]2[CH:19]=[C:20]([C:24]3[C:29]([NH:30][C:31](=[O:34])[CH2:32][Br:33])=[CH:28][CH:27]=[CH:26][C:25]=3[CH3:35])[CH:21]=[CH:22][CH:23]=2)(=[O:17])=[O:16])[CH:14]=1)=[NH:9])(C)(C)C.[C:39]([OH:45])([C:41]([F:44])([F:43])[F:42])=[O:40].C(Cl)Cl>>[F:42][C:41]([F:44])([F:43])[C:39]([OH:45])=[O:40].[Br:33][CH2:32][C:31]([NH:30][C:29]1[CH:28]=[CH:27][CH:26]=[C:25]([CH3:35])[C:24]=1[C:20]1[CH:21]=[CH:22][CH:23]=[C:18]([S:15]([C:13]2[CH:14]=[C:10]([C:8](=[NH:7])[NH2:9])[S:11][C:12]=2[S:36][CH3:37])(=[O:17])=[O:16])[CH:19]=1)=[O:34]Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
({4-[6′-(2-bromo-acetylamino)-2′-methyl-biphenyl-3-sulfonyl]-5-methylsulfanyl-thiophen-2-yl}-imino-methyl)-carbamic acid tert-butyl ester (22 mg, 0.034 mmol, as prepared in Example 246, step a) was stirred in a mixture of TFA/DCM (1:1, 4 mL) for 1 h at rt. The reaction was concentrated in vacuo and the resulting residue was purified using RP-HPLC (10–50% CH3CN in H2O with 0.1% TFA over 30 min) to afford 15 mg (68%) of the title compound as a clear glassy solid (purity>99.9% by analytical RP-HPLC). ESI-MS (m/z): Calcd. for C21H20BrN3O3S3: 538.0 (M+H); found: 538.0 and 540.0
Aufarbeitung
- concentrationThe reaction was concentrated in vacuo
- customthe resulting residue was purified
- customRP-HPLC (10–50% CH3CN in H2O with 0.1% TFA over 30 min)
Quellen und Nachweise
- ORD-Eintrag
- ord-62fa89c89bdf4a94828ab2254d0233e4
- Quelldatensatz
- uspto-grants-2006_09
- Patentnummer
- US07109354B2
Verknüpfte Notizen
Wird geladen…